Product Images Fintepla

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 28 images provide visual information about the product associated with Fintepla NDC 43376-322 by Ucb, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Chemical Structure - fintepla 01

Figure 1 - fintepla 02

Figure 2 - fintepla 03

The text is indicating a chart or table that shows the proportion of patients and percentage reduction from baseline in convulsive seizure frequency. No further information is available from the given text.*

Figure 3 - fintepla 04

ifu4 - fintepla 05

Description: This is a medication package that includes one bottle of FINTEPLA Oral Solution with a concentration of 2.2 mg/mL, as well as two oral syringes.*

ifu5 - fintepla 06

This text is a product description for two sets of oral syringes. The first set contains two syringes with a capacity of 3mL each and dose markings in 0.1 mL increments. The second set contains two syringes with 6mL capacity each and dose markings in 0.5 mL increments. These syringes seem to be designed for measuring and administering medication orally.*

ifu6 - fintepla 07

This text is describing the parts of a syringe which include the tip, barrel, base, and plunger.*

ifu7 - fintepla 08

ifu8 - fintepla 09

ifu9 - fintepla 10

ifu10 - fintepla 11

ifu11 - fintepla 12

ifu12 - fintepla 13

ifu13 - fintepla 14

ifu15 - fintepla 15

ifu16 - fintepla 16

This is a description of a 3 mL syringe that has dose markings in 0.1 mL increments. The text does not provide any further information.*

ifu17 - fintepla 17

This text indicates that the 6 mL syringe has dose markings in increments of 0.5 mL. It does not give any additional context or information.*

ifu18 - fintepla 18

ifu19 - fintepla 19

ifu20 - fintepla 20

ifu21 - fintepla 21

ifu22 - fintepla 22

ifu23 - fintepla 23

30 mL Bottle Label - fintepla 24

This is a medication called Fmtepla which contains fenfluramine in an oral solution. The NDC code is 43376-322-30 and each bottle contains 30mL of liquid with a concentration of 2.2 mg/mL. It is only for oral use and should be stored at a controlled room temperature between 68°F to 77°F (20°C to 25°C). The pharmacist must dispense the enclosed medication guide to each patient. The unused portion of the bottle should be discarded 3 months after first opening. The medication is recommended by Zogenix Inc. in Emeryville, CA. The recommended dosage should be consulted with the prescribing information.*

30 mL Carton Label - fintepla 25

This is a description of Finteplar (fenfluramine) as an oral solution with a concentration of 2.2 mg/mL. It is recommended to see the prescribing information for the dosage. The medication guide should be given to each patient, and the drug should be stored at a controlled room temperature between 68°F and 77°F (20°C to 25°C). The contents include one 30 mL bottle, and the unused portion should be discarded after 3 months from the first opening.*

360 mL Bottle Label - fintepla 26

This is a medication labeled with the NDC code 43376-322-36. It is an oral solution with a concentration of 2.2 mg/mL, and it is stored at controlled room temperature. The medication is only for oral use and should be used as directed, with the recommended dosage being provided in the prescribing information. The pharmacist is instructed to dispense a medication guide to each patient. The medication should not be refrigerated or frozen and any unused portion should be discarded 3 months after first opening.*

360 mL Carton Label - fintepla 27

Fintepla is an oral solution medication containing 2.2 mg/mL of fenfluramine and is intended for oral use. It is recommended to see the prescribing information for the recommended dosage. Each medication guide should be dispensed to patients, and the contents of one 360 ml bottle should be used. The medication should be stored at a controlled temperature of 68°F to 77°F (20°C to 25°C) and not refrigerated or frozen. The unused portion should be discarded within three months after the first opening, as stated in the NDC 43376-322-36.*

fintepla 28

The document appears to be a graph representing the percentage reduction from baseline in drop seizure frequency in patients. The graph compares the effects of three different drugs: placebo, BFINTEPLA 0.2 mg/kg/day, and WFINTEPLA 0.7 mg/kg/day. The x-axis of the graph represents the different percentage ranges of reduction, while the y-axis represents the different drugs. It appears that both BFINTEPLA and WFINTEPLA have a significantly greater effect on reducing drop seizure frequency than placebo.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.

Table of Contents